Russland ist am 24. Februar 2022 in die Ukraine eingefallen. Stehen Sie mit der Ukraine und unterstützen Sie uns im Kampf für Freiheit und Demokratie in Europa.  Stehen Sie mit der Ukraine!  Anmelden
search
Die #1 Medizintourismusplattform seit 2014

Beste Leberkrebs Stadium 2 Onkologen in der Türkei - TOP -32 Ärzte

author
Der Inhalt entspricht den Redaktionsrichtlinien von Bookimed und wurde auf Qualität geprüft
Fahad Mawlood - Allgemeinarzt. Gewinner von 4 wissenschaftlichen Preisen. Er diente in Westasien. Ehemaliger Teamleiter eines medizinischen Teams zur Betreuung arabischsprachiger Patienten. Jetzt Fahad ist verantwortlich für die Datenverarbeitung und die Genauigkeit der medizinischen Inhalte.
Yesim Yildirim
Klinischer Onkologe/-in
20 Jahre der Erfahrung
4.6
453 Rezensionen
Türkei, Istanbul
Anadolu Medical Center

Yesim Yildirim

Klinischer Onkologe/-in
20 Jahre der Erfahrung

Akkredititationen:

European Society of Medical Oncology
European School of Oncology

Dr. Yesim Yıldırım ist Professor für Medizinische Onkologie am Anadolu Medical Center und Mitglied der European Society of Medical Oncology (ESMO). Sie ist auf Krebsimmuntherapie und zielgerichtete Therapien, Diagnostik und Behandlung bösartiger Neubildungen spezialisiert und hat über 80 internationale und nationale Publikationen, Abstracts und Bücher veröffentlicht. Sie hat außerdem einen MBA in Healthcare Management und spricht Englisch, Russisch und Türkisch.

Mehr lesen
Mustafa Solak
Klinischer Onkologe/-in
18 Jahre der Erfahrung
4.5
109 Rezensionen
Türkei, Istanbul
Hisar Intercontinental Hospital

Mustafa Solak

Klinischer Onkologe/-in
18 Jahre der Erfahrung

Mustafa Solak, MD, ist ein Arzt, der seinen Abschluss an der Medizinischen Fakultät der Hacettepe-Universität gemacht hat und Aufenthalte am Lehr- und Forschungskrankenhaus Istanbul Sisli Etfal und ein Stipendium am Krebsinstitut der Hacettepe-Universität absolviert hat. Er ist spezialisiert auf Brustkrebs, Hodenkrebs, Eierstockkrebs, Lungenkrebs, Kopf-Hals-Krebs und Magen-Darm-Krebs. Er hat auch am MD Anderson Cancer Center der University of Texas, dem Corum Training Hospital der Hitit University und dem Medical Park Hospital gearbeitet.

Mehr lesen
Serkan Keskin
Klinischer Onkologe/-in
23 Jahre der Erfahrung
4.6
244 Rezensionen
Türkei, Istanbul
Memorial Sisli Hospital

Serkan Keskin

Klinischer Onkologe/-in
23 Jahre der Erfahrung

Onkologe, Spezialist für die Behandlung von Brustkrebs

Mehr lesen
Elnur Sahibov
Strahlenonkologe/-in
8 Jahre der Erfahrung
4.2
31 Rezensionen
Türkei, Istanbul
Emsey Hospital

Elnur Sahibov

Strahlenonkologe/-in
8 Jahre der Erfahrung

Lizenzierter Radioonkologe mit 8 Jahren medizinischer Ausbildung, einschließlich Grundstudium an der Medizinischen Fakultät der Marmara-Universität (2004-2011) und Spezialisierung auf Radioonkologie an der Medizinischen Fakultät der Marmara-Universität (2012-2016). Frühere Ausbildung an der Sixteen Numbered Shirvan School (Aserbaidschan) High School (1998-2004).

Mehr lesen
Dr Saban Secmeler
Klinischer Onkologe/-in
12 Jahre der Erfahrung
4.4
14 Rezensionen

Dr Saban Secmeler

Klinischer Onkologe/-in
12 Jahre der Erfahrung
Türkei, Istanbul
Hermes Clinics
Abdullah Sakin
Onkologe/Mammologe/-in
17 Jahre der Erfahrung
4.0
1 Rezensionen
Türkei, Istanbul
Medipol Bahçelievler Hospital

Abdullah Sakin

Onkologe/Mammologe/-in
17 Jahre der Erfahrung
 Experience2022 PRIVATE MEDIPOL BAHÇELİEVLER HOSPITAL 2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital, Medical Oncology Clinic Education Officer 2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital 2020 - 2021 Yüzüncü Yıl University Faculty of Medicine 2020 - 2021 Head of the Department of Medical Oncology, Yüzüncü Yıl University Faculty of Medicine, Assoc. Dr.   2018 - 2021 Lecturer - Yüzüncü Yıl University Faculty of Medicine, Head of Medical Oncology Department   2018 - 2021 Yüzüncü Yıl University Faculty of Medicine 2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital 2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital, Medical Oncology Clinic, Sub-branch assistant 2012 - 2015 Kanuni Sultan Süleyman Training and Research Hospital, Internal Medicine specialist 2012 - 2015 Suleiman the Magnificent Training and Research Hospital, 2008 - 2012 Haseki Training and Research Hospital 2006 - 2008 Kızıltepe No. 3 Health Center General Practitioner.  Education2018İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji2018İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji, İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji2012İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları, İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları2012İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları2007Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi, Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi Mehr lesen
4.0
1 Rezensionen
Arztbesuch preis auf anfrage
Strahlentherapie bei Darmkrebs $4000 - $6000
Weitere Behandlungen
Evrim Metcalfe
Strahlenonkologe/-in
26 Jahre der Erfahrung
4.0
1 Rezensionen
Türkei, Istanbul
Medipol Bahçelievler Hospital

Evrim Metcalfe

Strahlenonkologe/-in
26 Jahre der Erfahrung
Experience 2021 - 2022 Clinical Manager of Radiation Oncology, Medicana International Istanbul Hospital 2021 - 2022 Department of Radiation Oncology, Biruni University Faculty of Medicine 2020 - 2021 Clinical Manager of Radiation Oncology, Medicana International Istanbul Hospital 2017 - 2020 Clinical Manager of Radiation Oncology, Neolife Medical Center 2016 - 2017 Department of Radiation Oncology, Eskişehir Osmangazi University Faculty of Medicine 2011 - 2016 Department of Radiation Oncology, Eskişehir Osmangazi University Faculty of Medicine 2010 - 2011 Department of Radiation Oncology, Eskişehir Osmangazi University Faculty of Medicine 2008 - 2010 Radiation Oncology Clinic, Samsun Training and Research Hospital (Education Coordinator) 2006 Medical Faculty, Dokuz Eylül University 2006 - 2008 Radiation Oncology Clinic, Samsun Mehmet Aydın State Hospital (Compulsory Service) 2000 - 2006 Medical Faculty, Dokuz Eylül University   Education 2022 Biruni University Faculty of Medicine, Department of Radiation Oncology, Faculty Member, Professor Doctor 2022 Anadolu University Open Education Faculty Undergraduate Program, Cultural Heritage and Tourism 2021 Feyziye Schools Foundation Işık University Health Services Vocational School, Faculty Member, Associate Professor Doctor 2017 Eskişehir Osmangazi University Faculty of Medicine, Department of Radiation Oncology, Faculty Member 2017 Eskişehir Osmangazi University Faculty of Medicine, Department of Radiation Oncology, Associate Professor Doctor 2006 Samsun Training and Research Hospital, Specialist Doctor, Compulsory Service 2006 Dokuz Eylül University Faculty of Medicine, Department of Radiation Oncology, Medical Specialization 1998 Ege University, Faculty of Medicine     Mehr lesen
4.0
1 Rezensionen
Arztbesuch preis auf anfrage
Strahlentherapie bei Darmkrebs $4000 - $6000
Weitere Behandlungen
Fatih Oruc
Strahlenonkologe/-in
24 Jahre der Erfahrung
2.0
2 Rezensionen

Fatih Oruc

Strahlenonkologe/-in
24 Jahre der Erfahrung
Türkei, Istanbul
Istanbul Oncology Hospital
Ilker Nihat Okten
Klinischer Onkologe/-in
18 Jahre der Erfahrung
2.0
2 Rezensionen

Ilker Nihat Okten

Klinischer Onkologe/-in
18 Jahre der Erfahrung
Türkei, Istanbul
Istanbul Oncology Hospital
Nese Guney
Klinischer Onkologe/-in
26 Jahre der Erfahrung

Nese Guney

Klinischer Onkologe/-in
26 Jahre der Erfahrung
Türkei, Istanbul
Biruni University Hospital
Sezer Saglam
Klinischer Onkologe/-in
27 Jahre der Erfahrung
5.0
13 Rezensionen
Türkei, Istanbul
Florence Nightingale Hospital

Sezer Saglam

Klinischer Onkologe/-in
27 Jahre der Erfahrung
Professional ExperienceGayrettepe Florence Nigthingale HospitalMedical Oncology DepartmentBesiktas/Istanbul/Turkey (ongoing) Education:He became Professor (22/April /2016)Medical Oncology Attending Phys.in Gastrointestinal Oncology (January 2005 ,2009)Istanbul University Oncology Institue,Department of Medical Oncology Medical Oncology Fellowship (December 2001-December2004)Istanbul University, Istanbul Medical Faculty Hemodialysis Traning (May1996-January1997)Istanbul University ,bCerrahpasa Medical Faculty Internal Medicine Residency (November 1991-November 1996)Istanbul University ,bCerrahpasa Medical Faculty Ege University Medical Faculty (1985-1991) Professional Experience February 1999-November 2001Metropolitan Florence Nigthingale HospitalAmerican Cancer Center, Gayrettepe/İstanbul April1997- October 1998Bayraktar Dialysis CenterGüngören/ Istanbul Membership Turkish Medical Oncology AssociationENET(European Neuroendocrine Tumour Society)ESMOASCOMehr lesen
Muhammed Gomec
Dickdarmchirurg/-in
15 Jahre der Erfahrung
5.0
1 Rezensionen

Muhammed Gomec

Dickdarmchirurg/-in
15 Jahre der Erfahrung
Türkei, Sivas
Medicana Sivas Hospital
Alandag Celal
Klinischer Onkologe/-in
15 Jahre der Erfahrung
5.0
1 Rezensionen

Alandag Celal

Klinischer Onkologe/-in
15 Jahre der Erfahrung
Türkei, Sivas
Medicana Sivas Hospital
Seyda Gunduz
Klinischer Onkologe/-in
14 Jahre der Erfahrung
4.3
16 Rezensionen

Seyda Gunduz

Klinischer Onkologe/-in
14 Jahre der Erfahrung
Türkei, Istanbul
Istinye Universität Liv Krankenhaus Bahcesehir
Nail Paksoy
Onkologe/Mammologe/-in
13 Jahre der Erfahrung
4.0
1 Rezensionen
Türkei, Istanbul
Medipol Bahçelievler Hospital

Nail Paksoy

Onkologe/Mammologe/-in
13 Jahre der Erfahrung

Akkredititationen:

ESMO Board Certification in Medical Oncology
PROFESSIONAL EXPERIENCE2011-2012Erzurum Koprukoyu State HospitalDepartment: General Medicine2012-2017Istanbul University Cerrahpaşa Medical FacultyDepartment: Internal Medicine06/2017-10/2017Istanbul Gaziosmanpasa Taksim Training and Research HospitalDepartment: Internal Medicine10/2017-11/2018Istanbul University Istanbul Medical FacultyDepartment: Allergy and Immunology Fellowship2018/2022Istanbul University Oncology InstituteDepartment: Medical Oncology Fellowship2022-2023Tekirdag City HospitalDepartment: Medical Oncology Specialist2023-presentIstanbul Medipol University Medipol Bahcelievler Private HospitalDepartment: Medical Oncology Assoc. Prof. EDUCATION2005-2011Medical EducationSivas Cumhuriyet University Medical Faculty, Sivas, Turkey2012-2017Internal MedicineIstanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey2017-2018Allergy-Immunology FellowshipIstanbul University Istanbul Medical FacultyDepartment of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey2018-2022Medical Oncology FellowshipIstanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey2022ESMO Board Certification in Medical Oncology10th September 2022 in Paris, France.2023Medical Oncology Assoc. Prof.Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey INTERNATIONAL CLINICAL TRIALS:1. Astefania - ROCHETitle: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative TherapyRole: Subinvestigator2. PFİZERTitle: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLCRole: Subinvestigator3. RECITE - AMGENTitle: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal CancerRole: Subinvestigator4. NAVIGATE - BAYERTitle: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsRole: Subinvestigator5. RUBY - Tesaro (PRA)Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial CancerRole: Subinvestigator6. ENGOT-ov43/GOG-3036 - MSDTitle: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)Role: Subinvestigator7. ASTRA ZENECATitle: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.Role: Subinvestigator8. ROSY-O - ASTRA ZENECATitle: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With OlaparibRole: Subinvestigator INTERNATIONAL PUBLICATIONSI. Published journal articles indexed by SCI, SSCI, and AHCIWeekly Paclitaxel in Classic Kaposi SarcomaAuthors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.Journal: Medicine, 102(5)Carboplatin Desensitization in Ovarian CarcinomaAuthors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.Journal: Medicine, 101(45), e31726High-Dose Chemotherapy for Ewing’s SarcomaAuthors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.Journal: Medicine, 101(49), e32213Multidrug Refractory TFE3(+) Renal Cell CarcinomaAuthors: Paksoy, Nail, et al.Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221Crizotinib Efficacy in NSCLC with MET AlterationsAuthors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.Journal: Medicine, 101(50), e32368Clinicopathological Features in ALK Mutant NSCLCAuthors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.Journal: Medicine, 101(34)PSMA-Based Tumor Burden in Prostate CancerAuthors: HAS SIMSEK, Duygu, et al.Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690Atezolizumab in Metastatic Urothelial CarcinomaAuthors: TURAL, Deniz, et al.Journal: European Urology Focus, 2021, 7.5: 1061-1066Pulmonary Sarcomatoid CarcinomaAuthors: FERHATOGLU, Ferhat, et al.Journal: Oncology Research and Treatment, 2021, 44.11: 590-601Prognostic Factors in Atezolizumab-Treated Urothelial CarcinomaAuthors: TURAL, Deniz, et al.Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513Atezolizumab with Chemotherapy in Small Cell Lung CancerAuthors: GÜRBÜZ, Mustafa, et al.Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic CancerAuthors: AY, Seval, et al.Journal: Journal of Chemotherapy, 2022, 1-7Trastuzumab Emtansine in Older HER2-Positive Breast Cancer PatientsAuthors: CIL, Ibrahim, et al.Journal: Tumori Journal, 2022, 108.1: 19-25Real-Life Efficacy of Osimertinib in Advanced NSCLCAuthors: HIZAL, Mutlu, et al.Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508ALK-Positive Cells Percentage and Alectinib EfficacyAuthors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148Real-World Data on Alectinib in ALK-Positive NSCLCAuthors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.Journal: Future Oncology, 18(23), 2573-2582Prognostic Factors in Metastatic RCC with T790M MutationAuthors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.Journal: Journal of Cancer Research and TherapeuticsFLOT Regimen in Metastatic Gastric CancerAuthors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.Journal: Journal of Cancer Research and TherapeuticsDesensitization Protocol in Lenalidomide Hypersensitivity ReactionsAuthors: DEMIR, Semra, et al.Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397Factors Associated with Diagnostic Skin Test Positivity in PPI HypersensitivityAuthors: ÖZDEMIR, Seçil Kepil, et al.Journal: Allergy, 2019, 74.6: 1187-1190Efficacy of Capecitabine and Temozolomide in Neuroendocrine TumorsAuthors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.Journal: The Oncologist, oyad257Subsequent Treatments in Hormone-Positive Breast Cancer ProgressionAuthors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.Journal: BMC cancer, 23(1), 192Termination of Trastuzumab in HER2-Positive Metastatic Breast CancerAuthors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.Journal: Scientific Reports, 13(1), 8779Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast CancerAuthors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.Journal: Journal of Cancer Research and Clinical Oncology, 1-9Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast CancerAuthors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.Journal: European Journal of Breast Health, 19(2), 128Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast CancerAuthors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.Journal: Future Oncology, 19(10), 727-736Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma PatientsAuthors: Dogan, I., Paksoy, N., & Basaran, M.Journal: Journal of Cancer Research and TherapeuticsSingle-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma PatientsAuthors: Dogan, I., Paksoy, N., & Basaran, M.Journal: Journal of Cancer Research and TherapeuticsOutcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain MetastasesAuthors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.Journal: Journal of Cancer Research and TherapeuticsFLOT Regimen in First-Line Treatment of Metastatic Gastric CancerAuthors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.Journal: Journal of Cancer Research and TherapeuticsPrognostic Factors of Perioperative FLOT Regimen in Operable Gastric CancerAuthors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.Journal: [Not specified]Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi SarcomaAuthors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.Journal: Medicine, 102(39), e35383Comparison of Second-Line Treatments in Metastatic Renal Cell CarcinomaAuthors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.Journal: Medicine, 102(41), e35245Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGYPredictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of PulmonologyLaterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye Thesis:Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combinationAuthors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group studyAuthors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancerAuthors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)Efficacy of temozolomide in pretreated patients with metastatic sarcomaAuthors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumorsAuthors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcomaAuthors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastasesAuthors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinomaAuthors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk studyAuthors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiencesAuthors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)  Mehr lesen
4.0
1 Rezensionen
Arztbesuch preis auf anfrage
Strahlentherapie bei Darmkrebs $4000 - $6000
Weitere Behandlungen
Kenan Demirbakan
Onkologe/Mammologe/-in
24 Jahre der Erfahrung

Kenan Demirbakan

Onkologe/Mammologe/-in
24 Jahre der Erfahrung
Türkei, Gaziantep
SANKO Üniversitesi Hastanesi
Hamza Ugur Bozbey
Klinischer Onkologe/-in
10 Jahre der Erfahrung

Hamza Ugur Bozbey

Klinischer Onkologe/-in
10 Jahre der Erfahrung
Türkei, Istanbul
Uniqacare Clinic
Emrah Eraslan
Klinischer Onkologe/-in
19 Jahre der Erfahrung
2.0
1 Rezensionen
Türkei, Ankara
Private Koru Ankara Hospital

Emrah Eraslan

Klinischer Onkologe/-in
19 Jahre der Erfahrung
Associate Professor Dr. Emrah Eraslan graduated from Ankara University Faculty of Medicine in 2005. From 2006 to 2011, he worked as a research assistant in the Department of Internal Medicine at Ankara University Faculty of Medicine and became an internal medicine specialist in 2011. Between 2011 and 2013, he worked as an internal medicine specialist and chief physician at Dr. Nafiz Körez Sincan State Hospital and Palu District State Hospital. From 2013 to 2016, he received medical oncology training at Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital and worked there until 2021. In 2023, he became an associate professor and contributed to his field with his publications throughout his career. He currently serves his patients at Koru Ankara Hospital. His medical interests include:Breast CancerProstate CancerLung CancerColorectal CancerStomach CancerOvarian CancerMehr lesen
Babek Tabandeh
4.2
20 Rezensionen
Türkei, Istanbul
Medical Park Istanbul

Akkredititationen:

Turkish Medical Association
Liver Transplantation Society
Istanbul Surgery Association
Turkey Obesity and Metabolic Surgery Society
American College of Surgeons
+1

Ausserordentlicher Professor für allgemeine und bariatrische Chirurgie. Spezialisiert auf laparoskopische (minimal-invasive) Chirurgie.

Mehr lesen
Alper Demirbaş
4.2
20 Rezensionen
Türkei, Istanbul
Medical Park Istanbul

Transplantologe, spezialisiert auf Lebertransplantation

Mehr lesen

Bookimed redaktionelle Richtlinie

Bookimed, eine führende globale Plattform für Medizintourismus, hat es sich zur Aufgabe gemacht, Kunden bei der Behandlung von Leberkrebs im Stadium 2 zu unterstützen, indem es fachkundige Unterstützung und vertrauenswürdige medizinische Lösungen für jede Situation bietet. Mithilfe eines intelligenten automatischen Rankingsystems werden transparente Kliniklisten erstellt, die von einem Datenwissenschaftler unter Einsatz von KI für Genauigkeit sorgfältig gepflegt werden. Die Plattform garantiert Authentizität, indem sie Bewertungen von echten Patienten nach ihren Behandlungen veröffentlicht. Bookimed bietet umfassende medizinische Lösungen mit Updates von Kliniken, um die Vertrauenswürdigkeit zu gewährleisten. Der Inhalt zur Behandlung von Leberkrebs im Stadium 2, der von erfahrenen medizinischen Autoren erstellt und von Spezialisten überprüft wurde, entspricht den redaktionellen Richtlinien von Bookimed und spiegelt das Engagement der Plattform für die Bereitstellung hochwertiger und klarer Gesundheitsinformationen wider. Für weitere Details oder Anfragen kontaktieren Sie uns bitte unter marketing@bookimed.com oder erfahren Sie hier mehr über uns und unsere Mission.

Experte des Medizinischen Beirats von Bookimed für Leberkrebs Stadium 2

Dr. Yesim Yıldırım ist Professor für Medizinische Onkologie am Anadolu Medical Center und Mitglied der European Society of Medical Oncology (ESMO). Sie ist auf Krebsimmuntherapie und zielgerichtete Therapien, Diagnostik und Behandlung bösartiger Neubildungen spezialisiert und hat über 80 internationale und nationale Publikationen, Abstracts und Bücher veröffentlicht. Sie hat außerdem einen MBA in Healthcare Management und spricht Englisch, Russisch und Türkisch.